ALX Oncology Holdings Inc ALXO.OQ ALXO.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for ALX Oncology Holdings Inc is for a loss of 45 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $2.50, about 79.3% above its last closing price of $0.52
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.45 | -0.46 | -0.58 | Missed | -25 |
Dec. 31 2025 | -0.62 | -0.67 | -0.55 | Beat | 17.9 |
Sep. 30 2024 | -0.78 | -0.78 | -0.58 | Beat | 25.6 |
Jun. 30 2024 | -0.77 | -0.77 | -0.76 | Beat | 1.7 |
Mar. 31 2024 | -0.85 | -0.84 | -0.71 | Beat | 15.1 |
Dec. 31 2023 | -0.81 | -0.84 | -0.93 | Missed | -10.5 |
Sep. 30 2023 | -0.82 | -0.87 | -1.24 | Missed | -42.5 |
Jun. 30 2023 | -0.88 | -0.88 | -0.84 | Beat | 4.5 |
This summary was machine generated August 4 at 20:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)